Načítá se...
SOUTHWEST ONCOLOGY GROUP TRIAL S9912: INTRAPERITONEAL CISPLATIN AND PACLITAXEL PLUS INTRAVENOUS PACLITAXEL AND PEGYLATED LIPOSOMAL DOXORUBICIN AS PRIMARY CHEMOTHERAPY OF SMALL-VOLUME RESIDUAL STAGE III OVARIAN CANCER
OBJECTIVE: While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach. METHODS: A multi-center phase 2 trial was conduct...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2703693/ https://ncbi.nlm.nih.gov/pubmed/19464730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2009.04.023 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|